Premium
Response of the Benign Hypertrophied Prostate to Treatment with an LHRH Analogue
Author(s) -
KEANE P. F.,
TIMONEY A. G.,
KIELY E.,
WILLIAMS GORDON,
STAMP G.
Publication year - 1988
Publication title -
british journal of urology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.773
H-Index - 148
eISSN - 1464-410X
pISSN - 0007-1331
DOI - 10.1111/j.1464-410x.1988.tb04299.x
Subject(s) - buserelin , medicine , muscle hypertrophy , urology , dihydrotestosterone , testosterone (patch) , prostate , residual volume , endocrinology , hormone , androgen , cancer , receptor , agonist , lung volumes , lung
Summary— Twenty patients with outflow tract obstruction secondary to benign prostatic hypertrophy were treated with an LHRH analogue, buserelin, for up to 6 months. Despite maintaining castrate levels of testosterone and achieving a significant reduction in tissue levels of dihydrotestosterone, no significant improvement was seen in flow rate or residual volume.